{"id":4602,"date":"2019-06-19T20:23:33","date_gmt":"2019-06-19T17:23:33","guid":{"rendered":"http:\/\/www.alfapatent-stanadvoka.com\/?p=4602"},"modified":"2021-01-12T21:09:45","modified_gmt":"2021-01-12T18:09:45","slug":"t2437-13","status":"publish","type":"post","link":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/t2437-13\/","title":{"rendered":"19.06.2019 \/T 2437\/13 \/CORONAVIRUS \/AMSTERDAM INSTITUTE"},"content":{"rendered":"

EP 1 526 175<\/a>\u00a0patenti itiraz s\u0131ras\u0131nda d\u00fczeltilmi\u015f bi\u00e7imde muhafaza edilince hem itiraz sahibi hem de patent sahibi temyize gitmi\u015ftir. Patent sahibi temyizle birlikte bir esas ve iki yard\u0131mc\u0131\/terditli talep dosyalam\u0131\u015ft\u0131r. Patent sahibi daha sonra itiraz sahibinin temyiz dilek\u00e7esine cevap verirken 3 ek yard\u0131mc\u0131 talep daha dosyalam\u0131\u015ft\u0131r. Yine patent sahibi Temyiz Kurulu\u2019nun ba\u011flay\u0131c\u0131 olmayan \u00f6n g\u00f6r\u00fc\u015f\u00fcne ve duru\u015fma davetine cevaben 3 adet ek terditli talep daha dosyalam\u0131\u015ft\u0131r. S\u00f6zl\u00fc duru\u015fma patent sahibi mevcudiyetinde ve itiraz sahibinin yoklu\u011funda ger\u00e7ekle\u015fmi\u015ftir. Burada patent sahibi 1-5 aras\u0131 taleplerini geri \u00e7ekip 6. terditli talebini ana talep olarak belirlemi\u015ftir. Ana talepte yer alan ilk \u00fc\u00e7 istem a\u015fa\u011f\u0131daki gibidir:<\/p>\n

– “1. An isolated and\/or recombinant nucleic acid having at least 95% sequence identity to a nucleic acid sequence as depicted in table 3 or comprising a sequence having at least 99% sequence identity to a nucleic acid sequence as depicted in figure 19.<\/p>\n

– 2. An isolated and\/or recombinant nucleic acid according to claim 1, comprising a sequence as depicted in table 3 or figure 19.<\/p>\n

– 3. An isolated and\/or recombinant proteinaceous molecule that is the ORF-2 Spike protein\/S-gene sequence as depicted in figure 22; or that is selected from the group consisting of:<\/p>\n

– the ORF 1ab replicase polyprotein sequence as depicted in figure 21;<\/p>\n

– the 3ClPro Coronavirus polyprotein processing endoprotease sequence as depicted in figure 21;<\/p>\n

– the RNA dependent RNA polymerase (pfam00680) sequence as depicted in figure 21;<\/p>\n

– the ExoN 3′ to 5′ Exonuclease and helicase sequence as depicted in figure 21;<\/p>\n

– the XendoU (homolog of) polyU-specific endoribonuclease sequence as depicted in figure 21;<\/p>\n

– the 2′-O-MT 2: S-adenosylmethionine-dependent ribose 2′-orthomehyltransferase sequence as depicted in figure 21;<\/p>\n

– the ORF-5 pfam01635, Corona_M, Coronavirus M matrix\/glycoprotein sequence as depicted in figure 23; and<\/p>\n

– the ORF la, replicase enzyme complex sequence as depicted in figure 20.”<\/p><\/blockquote>\n

Patent sahibinin \u00f6n g\u00f6r\u00fc\u015fe cevaben dosyalad\u0131\u011f\u0131 ana talep yeni tart\u0131\u015fma alanlar\u0131na mahal vermedi\u011finden ve itiraz sahibinin itirazlar\u0131n\u0131 gidermeye y\u00f6nelik oldu\u011fundan incelemeye kabul edilmi\u015ftir.<\/p>\n

D\u00fczeltilmi\u015f istemler EPC\u00a0Kural 43(6)<\/a>\u2019ya ayk\u0131r\u0131 bi\u00e7imde tablolara at\u0131f yapmaktad\u0131r. \u0130tiraz sahibi bu hususa dikkat \u00e7ekmektedir. Ayr\u0131ca \u0130stem 17, 22 ve 23\u2019teki \u201cilgili hastal\u0131k \/related disease)\u201d ifadesinin EPC\u00a0Md. 84<\/a>\u00a0gereklerini ihlal etti\u011fi \u00f6ne s\u00fcr\u00fclm\u00fc\u015ft\u00fcr. Bu nedenle d\u00fczeltilmi\u015f istem tak\u0131m\u0131nda normalde itiraz gerek\u00e7esi olmayan ancak d\u00fczeltilmi\u015f olmalar\u0131 nedeniyle a\u00e7\u0131kl\u0131k bak\u0131m\u0131ndan inceleme konusu yap\u0131lan istemlerden \u00f6t\u00fcr\u00fc Md. 84 kusurlar\u0131n\u0131n bulunup bulunmad\u0131\u011f\u0131 konusunda Temyiz Heyeti karara varacakt\u0131r.<\/p>\n

S\u00f6zl\u00fc duru\u015fmaya kat\u0131lmamakla itiraz sahibi Temyiz Heyeti\u2019nin \u00f6n g\u00f6r\u00fc\u015f\u00fcne yorum yapma hakk\u0131n\u0131 kullanmam\u0131\u015ft\u0131r.\u00a0Dosyada yer alan D12 yay\u0131n\u0131n\u0131n dili Flamanca\u2019d\u0131r ve EPO resmi dillerinin birinde \u00e7evirisi sunulmad\u0131\u011f\u0131 i\u00e7in Temyiz Heyeti ilgili dok\u00fcman\u0131 dikkate almam\u0131\u015ft\u0131r.<\/p>\n

Temyiz Heyeti d\u00fczeltilmi\u015f istem tak\u0131m\u0131nda ana istemde tablolara at\u0131f olmas\u0131 ile ilgili Md. 84 itirazlar\u0131na ili\u015fkin olarak istem tablolardaki y\u00fczde aral\u0131klar\u0131n\u0131 net bir bi\u00e7imde ortaya koydu\u011fundan a\u00e7\u0131kl\u0131k itiraz\u0131n\u0131n haks\u0131z oldu\u011funa kanaat getirmi\u015ftir. \u201c\u0130lgili hastal\u0131k\u201d ibaresi de orijinal olarak tescil edilen istemlerde zaten yer ald\u0131\u011f\u0131ndan istemin d\u00fczeltilmi\u015f di\u011fer k\u0131s\u0131mlar\u0131 ile birlikte de\u011ferlendirildi\u011finde tek ba\u015f\u0131na yeni a\u00e7\u0131kl\u0131k itirazlar\u0131na yol a\u00e7mad\u0131\u011f\u0131 ve dolay\u0131s\u0131yla Md. 84 kusuruna kaynak olmad\u0131\u011f\u0131 de\u011ferlendirilmi\u015ftir.<\/p>\n

Dosya 1-39 aras\u0131 istemlere dayal\u0131 olarak patentin muhafaza edilmesi ve tarifnamenin adapte edilmesi karar\u0131yla birinci derece merci olarak \u0130tiraz Birimi\u2019ne geri g\u00f6nderilmi\u015ftir.<\/p>\n","protected":false},"excerpt":{"rendered":"

EP 1 526 175\u00a0patenti itiraz s\u0131ras\u0131nda d\u00fczeltilmi\u015f bi\u00e7imde muhafaza edilince hem itiraz sahibi hem de patent sahibi temyize gitmi\u015ftir. Patent<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112],"tags":[],"class_list":["post-4602","post","type-post","status-publish","format-standard","hentry","category-t-kararlar"],"_links":{"self":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/comments?post=4602"}],"version-history":[{"count":2,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4602\/revisions"}],"predecessor-version":[{"id":5085,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4602\/revisions\/5085"}],"wp:attachment":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/media?parent=4602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/categories?post=4602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/tags?post=4602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}